Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $1.37, $1.27 better than the analyst estimate of $0.10. Revenue for the quarter came in at $293.8 million versus the consensus estimate of $290.33 million.

GUIDANCE:

Emergent BioSolutions sees FY2024 revenue of $1.065-1.125 billion.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.